EHMT2 and head and neck squamous cell carcinoma: Inhibiting G9a catalytic activity preferentially hinders MYC binding to repressed genes and shifts repressed loci with H3K9me2 enrichment to active epigenetic states.216 Abnormal G9a expression is also a survival advantage of head and neck squamous cell carcinoma.